Nephrology
| IgA nephropathy
Nephrology
IgA nephropathy
IONIS-FB-LRx – an investigational RNA-targeting therapy: Phase 2 results in IgAN
book_2
Source:
Kidney Week 2024. Poster Session.
calendar_today
Published on Medfyle:
November 2024
In this medfyle
Growing evidence suggests complement activity is an important contributor to IgAN pathology. IONIS-FB-LRx targets Factor B mRNA in the liver, and updated Phase 2 data shared at Kidney Week 2024 support ongoing research into this investigational approach.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Infomedica-Medfyle. All rights reserved.
Source: Phase II Results of an Investigational RNA Therapeutic to Complement Factor B, IONIS-FB-LRx, for Treatment of IgA Nephropathy. Barbour S, et al. Presented at Kidney Week 2024; #TH-PO1205.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
